Pre-made Etesevimab benchmark antibody ( Whole mAb, anti-SARS-CoV-2 Spike RBD therapeutic antibody) for drug discovery and mechanism of action (MOA) research
Cat No.: GMP-Bios-ab-196
Anti-SARS-CoV-2 Spike RBD therapeutic antibody (Pre-made Etesevimab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Bamlanivimab/etesevimab is a combination of two monoclonal antibodies, bamlanivimab and etesevimab, administered together via intravenous infusion as a treatment for COVID-19. Both types of antibody target the surface spike protein of SARS-CoV-2.
Delivery impact due to the Coronavirus Outbreak
With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.
|Catalog No.||Package||Price(In USD)||Qty (Quantity)||Sum(In USD)|
|Products Name (INN Index)||Anti-SARS-CoV-2 Spike RBD therapeutic antibody (Pre-made Etesevimab biosimilar,Whole mAb)|
|Target||SARS-CoV-2 Spike RBD|
|Highest_Clin_Trial (Jan '20)||Approved|
|100% SI Structure||7c01:CD|
|99% SI Structure||None|
|95-98% SI Structure||None|
|Companies||Eli Lilly and Company;Institute of Microbiology of the Chinese Academy of Sciences;Shanghai Junshi Biosciences|